Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;9(5):1919-1930.
doi: 10.1007/s13300-018-0478-1. Epub 2018 Aug 10.

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting

Marc Evans  1 , Roopa Mehta  2 , Jens Gundgaard  3 , Barrie Chubb  4
Affiliations

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting

Marc Evans et al. Diabetes Ther. 2018 Oct.

Abstract

Background: Understanding which therapeutic innovations in diabetes represent the best value requires rigorous economic evaluation. Data from randomised controlled trials and observational studies indicate that insulin degludec has a hypoglycemia advantage versus insulin glargine 100 units/mL (glargine U100), the most widely prescribed basal insulin analogue in the UK. This analysis was done to more rigorously assess cost-effectiveness in a UK setting.

Methods: Data from two double-blinded, randomised, two-period crossover trials in type 1 (SWITCH 1) and type 2 (SWITCH 2) diabetes mellitus were used to assess the cost-effectiveness of degludec vs. glargine U100 with an economic model. Cost-effectiveness was analysed over a 1-year time horizon based on the different rates of hypoglycaemia and actual doses of insulin used, rather than glycaemic control due to the treat-to-target trial design.

Results: In type 1 diabetes mellitus, degludec was highly cost-effective compared with glargine U100, with an incremental cost-effectiveness ratio of £984 (increased costs of only £23/year and improvement in participant health of 0.0232 quality-adjusted life-years (QALYs)). In type 2 diabetes mellitus, it was estimated that quality of life was improved (0.0065 QALYs gain) with degludec compared with glargine U100 at an increased annual cost of £117 (incremental cost-effectiveness ratio, £17,939). One-way sensitivity analyses showed that the results were robust to changes in parameters in both type 1 and type 2 diabetes mellitus.

Conclusions: The rigorous design of the SWITCH trials, coupled with a representative patient population and a definition of hypoglycaemia that is relevant for real-world patients, makes the results of these trials highly generalisable. The within-trial analysis has the added value of being able to include doses and event rates directly from the trials. This short-term economic analysis estimated that IDeg would be cost-effective relative to IGlar U100 in both type 1 and type 2 diabetes mellitus in the UK.

Trial registration: SWITCH 1 (NCT02034513); SWITCH 2 (NCT02030600).

Funding: Novo Nordisk, Søborg, Denmark.

Keywords: Cost-effectiveness; Diabetes; Hypoglycaemia; Insulin degludec; Insulin glargine; Pharmacoeconomics; Type 1 diabetes; Type 2 diabetes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cost-effectiveness modelling of degludec. Reprinted with the permission of the publisher (Taylor & Francis Ltd, http://www.tandfonline.com) [12]. HRQoL health-related quality of life, hypo hypoglycaemia, ICER incremental cost-effectiveness ratio, IDeg insulin degludec, IGlar insulin glargine U100, QALY quality-adjusted life-year
See this image and copyright information in PMC

References

    1. Levin P. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics. Diabetes Obes Metab. 2008;10(Suppl. 2):66–75. doi: 10.1111/j.1463-1326.2008.00845.x. - DOI - PubMed
    1. Lane Wendy, Bailey Timothy S., Gerety Gregg, Gumprecht Janusz, Philis-Tsimikas Athena, Hansen Charlotte Thim, Nielsen Thor S. S., Warren Mark. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes. JAMA. 2017;318(1):33. doi: 10.1001/jama.2017.7115. - DOI - PMC - PubMed
    1. Wysham Carol, Bhargava Anuj, Chaykin Louis, de la Rosa Raymond, Handelsman Yehuda, Troelsen Lone N., Kvist Kajsa, Norwood Paul. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes. JAMA. 2017;318(1):45. doi: 10.1001/jama.2017.7117. - DOI - PMC - PubMed
    1. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944–950. doi: 10.1111/j.1463-1326.2012.01638.x. - DOI - PubMed
    1. Heise Tim, Korsatko Stefan, Nosek Leszek, Coester Hans Veit, Deller Sigrid, Roepstorff Carsten, Segel Stine, Kapur Rahul, Haahr Hanne, Hompesch Marcus. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. Journal of Diabetes. 2015;8(1):132–138. doi: 10.1111/1753-0407.12266. - DOI - PubMed

Associated data

LinkOut - more resources